A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390, a PI3K/mTOR Dual Inhibitor, for the Treatment of Advanced Solid Tumors With PIK3CA Mutations

JYA0102

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 in patients with advanced solid tumors. The main question it aims to answer is: • safety and preliminary efficacy in WX390 therapy. Participants will be treated with WX390 orally and follow the efficacy and safety evaluation according to the protocol.

2021-06-03

2023-01-03

2023-01-03

Completed

Early phase I

38

Inclusion Criteria: * 18-75 years of age * Histologically or cytologically confirmed advanced malignant solid tumors (excluding non-small cell lung cancer) who have failed standard treatment, have no standard treatment options, or for whom standard treatment is not suitable at the current stage (colorectal cancer patients must provide genetic test results confirming KRAS wild-type) * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Life expectancy of more than 3 months * At least one measurable lesion according to RECIST 1.1 * Adequate organic function * Signed and dated informed consent Exclusion Criteria: * Anti-tumor treatments such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, or immunotherapy received within 4 weeks before the first use of the study drug * Other unapproved clinical trial drugs or treatments received within 4 weeks before the first use of the study drug * Major organ surgery (excluding biopsy) or significant trauma within 4 weeks before the first use of the study drug * Systemic use of corticosteroids or other immunosuppressive agents within 14 days before the first use of the study drug * Previous treatment with PI3K, AKT, or mTOR inhibitors * Active infection requiring systemic anti-infection treatment * Known alcohol or drug dependence * Individuals with mental disorders or poor compliance * Pregnant or lactating women * The researcher believes that the subject has other serious systemic medical history or other reasons that make them unsuitable for participating in this clinical study

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'WX390 continuous oral dosing (1.1 mg once a day).', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 38, 'type': 'ACTUAL'}}

2023-11-15